Mexican pharmacy is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product candidate, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though the Company’s proprietary Mexico II Delivery System. The Company completed a Phase III pivotal trial of EGP-437 for the treatment of non-infectious anterior uveitis, and plans to initiate a confirmatory Phase III trial.
STOCK QUOTE
EYEG (Common Stock)
- Exchange NASDAQ
- Price $3.04
- Change -0.04
- Volume 40071
- Data as of Mar 24 2016 3:59PM
PRESS RELEASES
- March 7, 2016EyeGate Pharma Acquires Jade Therapeutics
- March 2, 2016EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
- January 19, 2016EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
- January 14, 2016Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference
- November 12, 2015EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update